Refractory inflammatory bowel disease

  • Karl H. Kim
  • Gary R. Lichtenstein
Article
  • 34 Downloads

Opinion statement

Therapeutic options for refractory colonic inflammation in patients with ulcerative colitis or Crohn’s disease have recently been expanded with the introduction of biologic therapies. Intravenous corticosteroids and cyclosporine A remain the standard therapies for severe ulcerative colitis. Monoclonal antibodies directed at tumor necrosis factor-α have proven to be exceptionally efficacious in patients with severe or refractory Crohn’s disease. Immunomodulatory therapy with azathioprine, 6-mercaptopurine, or methotrexate has demonstrated efficacy for maintenance of remission in patients with refractory ulcerative colitis or Crohn’s disease. The use of experimental biologic agents may be considered for those patients who fail to respond to or remain dependent on corticosteroids. Surgical intervention still remains for patients with severe colitis who fail to respond to medical therapy or develop life-threatening complications such as perforation or toxic megacolon.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Sands BE: Crohn’s disease. In Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. Edited by Feldman M, Friedman LS, Sleisenger MH: Philadelphia: WB Saunders; 2002: 2005–2038.Google Scholar
  2. 2.
    Rogers AI: Pseudo-intractability of inflammatory bowel disease. In Advanced Therapy of Inflammatory Bowel Disease, edn 1. Edited by Bayless TM, Hanauer SB. Hamilton, ON: BC Decker; 2001: 77–80.Google Scholar
  3. 3.
    Blackwell B: Drug therapy: patient compliance. N Engl J Med 1973, 289: 249–252.PubMedCrossRefGoogle Scholar
  4. 4.
    Truelove SC, Witts LJ: Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955, 2: 1041–1088.PubMedCrossRefGoogle Scholar
  5. 5.
    Srinivasan R, Su C, Lichtenstein GR: Medical therapy for Crohn’s disease. In In The Clinician’s Guide To Inflammatory Bowel Disease. Edited by Lichtenstein GR. Thorofare, NJ: Slack; 2003: 221–254.Google Scholar
  6. 6.
    Sandborn WJ, Feagan BG, Hanauer SB, et al.: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 2002, 122: 512–530.PubMedCrossRefGoogle Scholar
  7. 7.
    Jani N, Regueiro MD: Medical therapy for ulcerative colitis. Gastroenterol Clin North Am 2002, 31: 147–166.PubMedCrossRefGoogle Scholar
  8. 8.
    Faubion WA, Loftus EV, Harmsen WS, et al.: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121: 255–260.PubMedCrossRefGoogle Scholar
  9. 9.
    Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995, 1: 48–63.CrossRefGoogle Scholar
  10. 10.
    Cohen RD, Stein R, Hanauer SB: Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999, 94: 1587–1592.PubMedCrossRefGoogle Scholar
  11. 11.
    D’Haens G, Lemmens L, Geboes K, et al.: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001, 120: 1323–1329.PubMedCrossRefGoogle Scholar
  12. 12.
    van Assche G, D’Haens G, Noman M, et al.: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003, 125: 1025–1031.PubMedCrossRefGoogle Scholar
  13. 13.
    Harrison J, Hanauer SB: Medical treatment of Crohn’s disease. Gastroenterol Clin North Am 2002, 31: 167–184.PubMedCrossRefGoogle Scholar
  14. 14.
    Sandborn WJ: A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996, 91: 423–433.PubMedGoogle Scholar
  15. 15.
    Lewis JD, Schwartz JS, Lichtenstein GR: Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000, 118: 1018–1024.PubMedCrossRefGoogle Scholar
  16. 16.
    Nielsen OH, Vainer B, Rask-Madsen J: Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001, 15: 1699–1708.PubMedCrossRefGoogle Scholar
  17. 17.
    Yang YX, Lichtenstein GR: Methotrexate for the maintenance of remission in Crohn’s disease. Gastroenterology 2001, 120: 1553–1558.PubMedGoogle Scholar
  18. 18.
    Feagan BG, Rochon J, Fedorak RN, et al.: Methotrexate for the treatment of Crohn’s disease. N Engl J Med 1995, 332: 292–297.PubMedCrossRefGoogle Scholar
  19. 19.
    Feagan BG, Fedorak RN, Irvine EJ, et al.: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N Engl J Med 2000, 342: 1627–1632.PubMedCrossRefGoogle Scholar
  20. 20.
    Orth T, Peters M, Schlaak JF, et al.: Mycophenolate moeftil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000, 95: 1201–1207.PubMedCrossRefGoogle Scholar
  21. 21.
    Neurath MF, Wanitschke R, Peters M, et al.: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 1999, 44: 625–628.PubMedCrossRefGoogle Scholar
  22. 22.
    Fellermann K, Steffen M, Stein J, et al.: Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000, 14: 171–176.PubMedCrossRefGoogle Scholar
  23. 23.
    Fellermann K, Ludwig D, Stahl M, et al.: Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998, 93: 1860–1866.PubMedCrossRefGoogle Scholar
  24. 24.
    Sandborn WJ, Present DH, Isaacs K, et al.: Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125: 380–388. A randomized, placebo-controlled trial showing clinical improvement but not remission of fistulous Crohn’s disease with the use of oral tacrolimus.PubMedCrossRefGoogle Scholar
  25. 25.
    Blam ME, Stein RB, Lichtenstein GR: Integrating antitumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol 2001, 96: 1977–1997.PubMedGoogle Scholar
  26. 26.
    Targan SR, Hanauer SB, van Deventer SJ, et al.: A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. N Engl J Med 1997, 337: 1029–1035.PubMedCrossRefGoogle Scholar
  27. 27.
    Rutgeerts PJ, D’Haens G, Targan SR, et al.: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999, 117: 761–769.PubMedCrossRefGoogle Scholar
  28. 28.
    Su C, Salzberg BA, Lewis JD, et al.: Efficacy of antitumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002, 97: 2577–2584. Preliminary experience suggesting effectiveness of infliximab in the treatment of active ulcerative colitis.PubMedCrossRefGoogle Scholar
  29. 29.
    Stack WA, Mann SD, Roy AJ, et al.: Randomised controlled trial of CDP571 antibody to tumour necrosis factor-a in Crohn’s disease. Lancet 1997, 349: 521–524.PubMedCrossRefGoogle Scholar
  30. 30.
    Sandborn WJ, Feagan BG, Hanauer SB, et al.: An engineered human antibody to TNF (CDP571) for active Crohn’s disease: a randomized double-blind placebocontrolled trial. Gastroenterology 2001, 120: 1330–1338.PubMedCrossRefGoogle Scholar
  31. 31.
    Sands BE: Novel therapies for inflammatory bowel disease. Gastroenterol Clin North Am 1999, 28: 323–351.PubMedCrossRefGoogle Scholar
  32. 32.
    Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121: 1088–1094.PubMedCrossRefGoogle Scholar
  33. 33.
    Rutgeerts PJ, van Assche G, Noman M, et al.: Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003, 17: 185–192.PubMedCrossRefGoogle Scholar
  34. 34.
    Bauditz J, Haemling J, Ortner M, et al.: Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn’s disease. Gut 1997, 40: 470–474.PubMedGoogle Scholar
  35. 35.
    Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al.: An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn’s disease. Gastroenterology 1999, 117: 1278–1287.PubMedCrossRefGoogle Scholar
  36. 36.
    Ehrenpreis ED, Kane SV, Cohen LB, et al.: Thalidomide therapy in patients with refractory Crohn’s disease: an open-label trial. Gastroenterology 1999, 117: 1271–1277.PubMedCrossRefGoogle Scholar
  37. 37.
    Schreiber S, Fedorak RN, Nielsen OH, et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Gastroenterology 2000, 119: 1461–1472.PubMedCrossRefGoogle Scholar
  38. 38.
    Fedorak RN, Gangl A, Elson CO, et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn’s disease. Gastroenterology 2000, 119: 1473–1482.PubMedCrossRefGoogle Scholar
  39. 39.
    Sands BE, Bank S, Sninsky CA, et al.: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn’s disease. Gastroenterology 1999, 117: 58–64.PubMedCrossRefGoogle Scholar
  40. 40.
    Pullan RD, Rhodes J, Ganesh S, et al.: Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994, 330: 811–815.PubMedCrossRefGoogle Scholar
  41. 41.
    Sandborn WJ: Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol 1999, 94: 1161–1171.PubMedCrossRefGoogle Scholar
  42. 42.
    Panes J, Esteve M, Cabre E, et al.: Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology 2000, 119: 903–908.PubMedCrossRefGoogle Scholar
  43. 43.
    Ghosh S, Goldin E, Gordon FH, et al.: Natalizumab for active Crohn’s disease. N Engl J Med 2003, 348: 24–32. An important randomized controlled trial demonstrating the effectiveness of natalizumab in active Crohn’s disease. It showed improvement of remission rates at multiple time points.PubMedCrossRefGoogle Scholar
  44. 44.
    Slonim AE, Bulone L, Damore MB, et al.: A preliminary study of growth hormone therapy for Crohn’s disease. N Engl J Med 2000, 342: 1633–1677. A randomized, placebo-controlled trial suggesting benefit of human growth hormone in the treatment of chronically active Crohn’s disease.PubMedCrossRefGoogle Scholar
  45. 45.
    Lewis JD, Lichtenstein GR, Stein R, et al.: An open-label trial of the PPARg ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 2001, 96: 3323–3328. A novel pilot study documenting the first reported use of PPARã ligand as therapy for ulcerative colitis in humans.PubMedGoogle Scholar
  46. 46.
    Belluzzi A, Brignola C, Campieri M, et al.: Effect of an enteric-coated fish oil preparation on relapses in Crohn’s disease. N Engl J Med 1996, 334: 1557–1560.PubMedCrossRefGoogle Scholar
  47. 47.
    Drug Topics Red Book, edn 107. Montvale, NJ: Thompson PDR; 2003.Google Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Karl H. Kim
    • 1
  • Gary R. Lichtenstein
    • 1
  1. 1.Division of Gastroenterology, Department of MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations